01436naa a2200229 a 450000100080000000500110000800800410001902400380006010000200009824501170011826000090023530000160024452008100026065000140107065000170108465000110110165000110111270000180112370000180114170000190115977300280117821501642022-12-21       2022    bl uuuu     u00u1 u    #d7 a10.1007/978-3-031-08045-6_262DOI1 aPORTILHO, A. I.  aDifferent platforms, immune response modulators and challenges in SARS-COV-2 vaccination.h[electronic resource]  c2022  ap. 539-559.  aVaccination is one of the most powerful measures to control infectious diseases. Nowadays, technical advances allowed the recognition of key aspects of pathogen?host interaction and the spread of such information, which was applied in vaccine development. The urge to control the COVID-19 pandemic resulted in vaccines development in record time, approximately 1 year after the emergence of SARS-CoV-2. The use of classic and innovative vaccine platforms and adjuvants was employed at several locations, by different groups. Here, we discuss how the pandemic scenario influences vaccine development, the implications of the route of immunization and adjuvant choice for vaccines, and the need to consider all these aspects in relation to the current scenario, also preparing ourselves to future pandemics.  aImunidade  aImunização  aVacina  aVírus1 aCORREA, V. A.1 aGASPAR, E. B.1 aDE GASPARI, E.  tZurich: Springer, 2022.